Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Outsourcing
Cambrex will up capacity at Iowa facility
by Rick Mullin
November 21, 2020
| A version of this story appeared in
Volume 98, Issue 45
Credit: Cambrex
Cambrex will expand this facility by 30%.
Citing growing demand for small-molecule drug development and production, Cambrex says it will spend $50 million to expand its capacity to make active pharmaceutical ingredients in Charles City, Iowa. The project will add three large-scale manufacturing centers and one midscale center, increasing the site’s capacity by 30% when completed in 2022. The expansion—the third in 8 years at the site—is expected to create 25 jobs, bringing employment there to 400.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2025 American Chemical Society
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X